how big is Sampre Nutrition?

As of Jun 06, Sampre Nutrition Ltd has a market capitalization of 52.00 Cr, with recent net sales of 25.13 Cr and a net profit of -7.67 Cr over the last four quarters. Shareholder's funds are 22.47 Cr, and total assets amount to 44.75 Cr as of Mar'24.

Market Cap: Sampre Nutritions Ltd has a market capitalization of 52.00 Cr, categorizing it as a Micro Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes data from Mar'25, Dec'24, Sep'24, and Jun'24, is 25.13 Cr. The sum of Net Profit for the same period is -7.67 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is also on a Consolidated basis for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 22.47 Cr, while Total Assets amount to 44.75 Cr.

What does Sampre Nutrition do?

Sampre Nutritions Ltd manufactures sugar candies and operates in the FMCG sector, primarily producing for Cadbury India Ltd since 1996. As of March 2025, it reported net sales of 8 Cr and a net loss of 7 Cr, with a market cap of Rs 52 Cr.

Overview:<BR>Sampre Nutritions Ltd is engaged in the manufacturing of sugar candies and operates within the FMCG industry, classified as a micro-cap company.<BR><BR>History:<BR>Incorporated in 1991, Sampre Nutritions Ltd was promoted by The Gurbani Group and has been manufacturing candy products for Cadbury India Ltd since August 1996. The company entered into an agreement to manufacture "DAIRY MILK ECLAIRS" in 2000. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 8 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -7 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 52 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.85 <BR>Return on Equity: -35.54% <BR>Price to Book: 2.68<BR><BR>Contact Details:<BR>Address: P No 133 Indl Estate, Medchal Telangana: 501401 <BR>Phone: 91-08418-222427/28 <BR>Email: gurbani@gurbanigroup.in <BR>Website: http://www.sampreltd.com

Who are in the management team of Sampre Nutrition?

As of March 2022, the management team of Sampre Nutrition includes B K Gurbani (Managing Director), Vishal Ratan Gurbani (Vice President & Whole-Time Director), and four Independent Directors: Banala Jayaprakash Reddy, Umra Singh Sirohi, and Vimal Suresh, along with Deepak Bissa (Company Secretary & Compliance Officer).

As of March 2022, the management team of Sampre Nutrition includes the following individuals:<BR><BR>1. B K Gurbani - Managing Director<BR>2. Banala Jayaprakash Reddy - Independent Director<BR>3. Umra Singh Sirohi - Independent Director<BR>4. Vishal Ratan Gurbani - Vice President & Whole-Time Director<BR>5. Vimal Suresh - Independent Director<BR>6. Deepak Bissa - Company Secretary & Compliance Officer<BR><BR>These members play key roles in the governance and operational management of the company.

Has Sampre Nutrition declared dividend?

No Dividend History Available

Who are the peers of the Sampre Nutrition?

Sampre Nutrition's peers include Hind. Unilever, ITC, Nestle India, Britannia Inds., and others, with varying management risks and growth rates. Notably, Norben Tea has the highest 1-year return at 225.68%, while Sampre Nutrition has the lowest at -54.01%.

Peers: The peers of Sampre Nutrition are Hind. Unilever, ITC, Nestle India, Britannia Inds., Godrej Consumer, Oceanic Foods, NHC Foods, Norben Tea, and Italian.<BR><BR>Quality Snapshot: Excellent management risk is observed at ITC, Nestle India, and Britannia Inds., while Good management risk is found at Hind. Unilever and Godrej Consumer, and the rest have Below Average management risk. Growth is Good at NHC Foods, Average at Nestle India, and Below Average at Hind. Unilever, ITC, Britannia Inds., Godrej Consumer, Oceanic Foods, Sampre Nutrition, Norben Tea, and Italian. Capital Structure is Excellent at Hind. Unilever, ITC, Nestle India, Britannia Inds., Godrej Consumer, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Norben Tea at 225.68%, while Sampre Nutrition has the lowest at -54.01%. Sampre Nutrition's 1-year return is significantly worse than all peers. Additionally, NHC Foods has a negative six-month return of -71.96%.

Is Sampre Nutrition overvalued or undervalued?

As of June 5, 2025, Sampre Nutrition is considered overvalued with a risky valuation grade, reflected by a PE ratio of -7.39, an EV to EBITDA ratio of -19.19, and a troubling ROE of -35.54%, significantly underperforming its peers and the market with a year-to-date return of -60.75%.

As of 5 June 2025, Sampre Nutrition's valuation grade has moved from expensive to risky, indicating a significant shift in its perceived value. The company is currently assessed as overvalued. Key ratios highlight its precarious position: the PE ratio stands at -7.39, the EV to EBITDA ratio is at -19.19, and the ROE is a concerning -35.54%. <BR><BR>In comparison to its peers, Sampre Nutrition's metrics are starkly unfavorable; for instance, Hindustan Unilever has a PE ratio of 53.88, while Nestlé India boasts a PE of 75.2. This stark contrast underscores the challenges Sampre faces in the FMCG sector. Additionally, the company's stock performance has been disappointing, with a year-to-date return of -60.75%, significantly underperforming the Sensex's 5.62% return.

What is the technical trend for Sampre Nutrition?

As of June 4, 2025, Sampre Nutrition's technical trend has shifted to a moderate bearish stance, supported by bearish signals from Bollinger Bands, moving averages, and monthly MACD, despite some mildly bullish indicators on the weekly timeframe.

As of 4 June 2025, the technical trend for Sampre Nutrition has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD showing mildly bullish but the monthly MACD is bearish, indicating a divergence in trends. The Bollinger Bands are bearish on both weekly and monthly time frames, reinforcing the bearish outlook. Daily moving averages are also bearish. The KST shows a mildly bullish signal on the weekly but is bearish on the monthly, while the Dow Theory indicates a mildly bearish stance on the weekly with no trend on the monthly. Overall, the combination of these indicators suggests a bearish sentiment in the current market environment.

When is the next results date for Sampre Nutrition?

The next results date for Sampre Nutrition is July 18, 2025.

The next results date for Sampre Nutrition is scheduled for July 18, 2025.

Who are the top shareholders of the Sampre Nutrition?

The top shareholder of Sampre Nutrition is Wave Capital Ltd, holding 12.52% of the shares. Individual shareholders own 31.28%, with Brahma Gurbani as the largest promoter at 4.94%, and there are no pledged promoter holdings or investments from mutual funds or foreign institutional investors.

The top shareholders of Sampre Nutrition include Wave Capital Ltd, which holds the largest public share at 12.52%. Among individual shareholders, they collectively own 31.28% of the company. The promoter with the highest holding is Brahma Gurbani, who owns 4.94%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares.

Are Sampre Nutrition latest results good or bad?

Sampre Nutrition's latest Q2 FY26 results show significant improvements in net profit and revenue growth, but challenges remain with weak capital efficiency and declining long-term profitability. Overall, while there are positive signs, investors should be cautious due to ongoing structural weaknesses.

Sampre Nutrition's latest results for Q2 FY26 show a mixed performance. On the positive side, the company reported a net profit of ₹0.90 crores, which is a significant improvement of 650% year-on-year and a 26.76% increase from the previous quarter. Revenue also grew by 37.55% year-on-year to ₹10.00 crores, although it experienced an 8% decline compared to the previous quarter.<BR><BR>The operating margin improved to 19.50%, marking the highest level in seven quarters, indicating better cost management and operational efficiency. However, the company faces challenges with weak capital efficiency, as reflected in its average return on equity (ROE) of just 1.71%, which is among the lowest in its peer group.<BR><BR>While the quarterly results indicate a recovery from previous losses, the overall financial health remains concerning due to a flat annual performance in FY25, with a net loss of ₹7.00 crores. The company's long-term profitability has also been in decline, as evidenced by a negative five-year EBIT compound annual growth rate (CAGR) of -238.74%.<BR><BR>In summary, while there are positive signs in the latest quarterly results, the underlying issues of weak capital efficiency and long-term profitability challenges suggest that the results are not entirely good. Investors should approach with caution, considering both the recent improvements and the ongoing structural weaknesses.

Should I buy, sell or hold Sampre Nutrition?

How has been the historical performance of Sampre Nutrition?

Sampre Nutrition experienced a significant decline in financial health from March 2024 to March 2025, with net sales slightly decreasing and total expenditure rising sharply, resulting in a negative operating profit and a loss after tax of -7.67 Cr. Despite an increase in total assets, the company's financial outlook is concerning due to negative profit margins and escalating costs.

Answer:<BR>The historical performance of Sampre Nutrition shows a significant decline in financial health from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Sampre Nutrition reported net sales of 25.12 Cr, a slight decrease from 25.15 Cr in the previous year. Total operating income mirrored this trend, remaining nearly unchanged at 25.12 Cr compared to 25.15 Cr in March 2024. However, total expenditure saw a substantial increase to 28.99 Cr from 21.02 Cr, primarily driven by a rise in employee costs from 7.75 Cr to 10.81 Cr and other expenses escalating from 3.74 Cr to 9.82 Cr. This led to an operating profit (PBDIT) of -3.50 Cr, a stark contrast to the positive 4.25 Cr reported in the prior year. Consequently, profit before tax plummeted to -7.52 Cr from 0.49 Cr, resulting in a profit after tax of -7.67 Cr compared to a modest profit of 0.23 Cr in March 2024. The earnings per share also reflected this downturn, falling to -3.65 from 0.32. On the balance sheet, total liabilities surged to 115.43 Cr from 44.75 Cr, while total assets increased to the same figure, indicating a significant rise in the company's financial obligations. The book value per share improved to 42.44 from 26.75, but the overall financial outlook for Sampre Nutrition appears concerning, with negative profit margins and increasing costs overshadowing any positive asset growth.

Which are the latest news on Sampre Nutrition?

Why is Sampre Nutritions Ltd falling/rising?

As of 29-Dec, Sampre Nutritions Ltd's stock price is at 23.92, reflecting a slight decline and a total drop of -3.55% over the last two days. Despite a strong year-to-date return of +50.20%, long-term performance is concerning with a -35.29% decline over three years, compounded by weak fundamentals and high debt levels.

As of 29-Dec, Sampre Nutritions Ltd's stock price is experiencing a slight decline, currently at 23.92, reflecting a change of -0.01 (-0.04%). The stock has underperformed its sector by -0.28% today and has been on a consecutive fall for the last two days, accumulating a total decline of -3.55% during this period. <BR><BR>Over the past week, the stock has decreased by -5.27%, while its performance over the last month shows a significant drop of -25.94%. Despite a strong year-to-date return of +50.20%, the stock's long-term performance is concerning, with a -35.29% decline over the last three years. <BR><BR>The stock's moving averages indicate that it is currently higher than the 200-day moving average but lower than the 5-day, 20-day, 50-day, and 100-day moving averages, suggesting a short-term weakness. Additionally, while there has been a rise in investor participation, with delivery volume increasing by 75.02% against the 5-day average, the overall sentiment remains cautious due to weak long-term fundamentals. <BR><BR>The company has reported a -218.60% CAGR growth in operating profits over the last five years and has a high Debt to EBITDA ratio of 5.03 times, indicating low ability to service debt. Furthermore, the stock is considered risky due to negative EBITDA, and despite a return of 37.81% over the past year, profits have fallen by -642.9%. These factors contribute to the current decline in the stock price of Sampre Nutritions Ltd.